NCT06280482

Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: The University of Texas Health Science Center, Houston · Academic / Other
• Sex: All
• Age: 1 Year
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients.

Conditions

• Smooth Muscle Dysfunction Syndrome (SMDS)

Interventions

Type	Name	Description
DRUG	Nicotinamide riboside (NR)	Participants will take their weight-based dose of NR once daily by mouth with food for 60 days.

Timeline

• Start date: 2024-03-06
• Primary completion: 2027-07-25
• Completion: 2027-07-25
• First posted: 2024-02-28
• Last updated: 2025-09-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study